Day One Biopharmaceuticals (DAWN) News Today $6.67 -0.02 (-0.30%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$6.72 +0.04 (+0.67%) As of 06/13/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Bank of America Corp DE Has $260,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Bank of America Corp DE trimmed its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 89.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,534 shares of the compJune 15 at 3:18 AM | marketbeat.comDay One Appoints Michael Vasconcelles, M.D., as Head of Research and DevelopmentJune 10, 2025 | finance.yahoo.comDay One Appoints Michael Vasconcelles, M.D., as Head of Research and DevelopmentJune 10, 2025 | globenewswire.comH.C. Wainwright Maintains Buy Rating on Day One Biopharmaceuticals (DAWN), Keeps PTJune 5, 2025 | msn.comJonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA ApprovalJune 5, 2025 | msn.comDay One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301June 4, 2025 | seekingalpha.comDay One Biopharmaceuticals (NASDAQ:DAWN) Trading 9% Higher - Still a Buy?Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 9% - Here's WhyJune 3, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Millennium Management LLCMillennium Management LLC grew its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 80.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 192,100 shares of the company's stock after purchasing an additional 85June 2, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 4.9% - Should You Sell?Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 4.9% - Here's What HappenedMay 31, 2025 | marketbeat.comTwo Sigma Investments LP Cuts Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Two Sigma Investments LP lowered its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 33.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 271,776 shares of the company's stock aftMay 31, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Buy" from BrokeragesShares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have received a consensus recommendation of "Buy" from the eight brokerages that are presently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and onMay 24, 2025 | marketbeat.comNorthern Trust Corp Grows Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Northern Trust Corp lifted its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 10.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 547,050 shares of the company's stock after acquiring an additional 51,960 shares durMay 22, 2025 | marketbeat.comVestal Point Capital LP Sells 1,060,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Vestal Point Capital LP decreased its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 42.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,440,000 shares of thMay 21, 2025 | marketbeat.comTema Etfs LLC Invests $1.09 Million in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Tema Etfs LLC acquired a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 85,761 shares of the company's stock, valued at approMay 20, 2025 | marketbeat.comInsider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells 3,927 Shares of StockMay 20, 2025 | insidertrades.comJanus Henderson Group PLC Reduces Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Janus Henderson Group PLC cut its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 40.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,306,220 shares of the company's stock after sellingMay 18, 2025 | marketbeat.comParkman Healthcare Partners LLC Purchases 76,334 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Parkman Healthcare Partners LLC boosted its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 8.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,000,474 shares of the company's stock after buying an additionalMay 16, 2025 | marketbeat.comParkwood LLC Takes $3.48 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Parkwood LLC bought a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 275,000 shares of the company's stock, valued atMay 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $634,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchaMay 16, 2025 | marketbeat.comIs Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now?May 14, 2025 | finance.yahoo.comHudson Bay Capital Management LP Has $11.66 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Hudson Bay Capital Management LP lifted its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 27.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 920,108 shares of the company's stock after buying anMay 14, 2025 | marketbeat.comIs Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now?May 13, 2025 | msn.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by Dimensional Fund Advisors LPDimensional Fund Advisors LP grew its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 10.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 927,017 shares of the company's stockMay 12, 2025 | marketbeat.comHC Wainwright Analysts Lower Earnings Estimates for DAWNDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Equities researchers at HC Wainwright reduced their Q2 2025 earnings per share estimates for Day One Biopharmaceuticals in a research note issued on Wednesday, May 7th. HC Wainwright analyst A. Maldonado now forecasts that the companyMay 11, 2025 | marketbeat.comWedbush Has Positive Estimate for DAWN Q2 EarningsDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Research analysts at Wedbush raised their Q2 2025 EPS estimates for shares of Day One Biopharmaceuticals in a research note issued to investors on Wednesday, May 7th. Wedbush analyst R. Driscoll now anticipates that the company will pMay 11, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Acquired by Estuary Capital Management LPEstuary Capital Management LP increased its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 35.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,716May 11, 2025 | marketbeat.comEquities Analysts Set Expectations for DAWN FY2028 EarningsDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Equities research analysts at HC Wainwright dropped their FY2028 earnings per share (EPS) estimates for shares of Day One Biopharmaceuticals in a research report issued on Wednesday, May 7th. HC Wainwright analyst A. Maldonado now expMay 10, 2025 | marketbeat.comBrokers Offer Predictions for DAWN Q1 EarningsDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Research analysts at Wedbush issued their Q1 2026 EPS estimates for shares of Day One Biopharmaceuticals in a report released on Wednesday, May 7th. Wedbush analyst R. Driscoll expects that the company will post earnings per share ofMay 10, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 12-Month Low Following Analyst DowngradeDay One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 52-Week Low on Analyst DowngradeMay 10, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up Following Earnings BeatDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up on Strong EarningsMay 9, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Price Target Cut to $27.00 by Analysts at Needham & Company LLCNeedham & Company LLC lowered their target price on Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday.May 9, 2025 | marketbeat.comIs Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030?May 9, 2025 | insidermonkey.comHsbc Holdings PLC Makes New Investment in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Hsbc Holdings PLC bought a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 38,583 shares of the company's stock, valued at aMay 9, 2025 | marketbeat.comDay One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...May 8, 2025 | uk.finance.yahoo.comDay One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2025 Financial Results and Corporate ProgressMay 8, 2025 | finanznachrichten.deDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q1 2025 Earnings Call TranscriptMay 7, 2025 | msn.comDay One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Report Preview: What to ExpectMay 7, 2025 | finance.yahoo.comDay One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comDay One Biopharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 6, 2025 | seekingalpha.comDay One Reports First Quarter 2025 Financial Results and Corporate ProgressMay 6, 2025 | globenewswire.comAlyeska Investment Group L.P. Takes Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Alyeska Investment Group L.P. bought a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,512,187 shares of the company's stock, valued at apprMay 6, 2025 | marketbeat.comBoxer Capital Management LLC Acquires Shares of 1,189,943 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Boxer Capital Management LLC purchased a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,189,943 shares of the company's stock,May 4, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 838,751 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Price T Rowe Associates Inc. MD lessened its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 33.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,706,112 shares of the company's stoMay 4, 2025 | marketbeat.comRA Capital Management L.P. Cuts Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)RA Capital Management L.P. lessened its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 26.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,755,577 shares of the company's stock after selling 2,116,144 shares duMay 3, 2025 | marketbeat.comDay One Biopharmaceuticals (DAWN) Projected to Post Earnings on TuesdayDay One Biopharmaceuticals (NASDAQ:DAWN) will be releasing its Q1 2025 earnings after the market closes on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-day-one-biopharmaceuticals-inc-stock/)May 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 100,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Adage Capital Partners GP L.L.C. cut its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 11.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 800,000 shares of the company's stock after selling 100,000 shares during tApril 30, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Buy" by AnalystsDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has earned an average rating of "Buy" from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strongApril 28, 2025 | marketbeat.comRenaissance Technologies LLC Purchases 148,900 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Renaissance Technologies LLC grew its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 157.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 243,740 shares of the company's stock after buying an addApril 26, 2025 | marketbeat.comResearch Analysts Offer Predictions for DAWN Q1 EarningsDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Wedbush decreased their Q1 2025 EPS estimates for Day One Biopharmaceuticals in a report issued on Monday, April 21st. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.45) for the quarteApril 25, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 5% - Here's WhyDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Up 5% - Should You Buy?April 23, 2025 | marketbeat.com Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address DAWN Media Mentions By Week DAWN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DAWN News Sentiment▼0.890.89▲Average Medical News Sentiment DAWN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DAWN Articles This Week▼44▲DAWN Articles Average Week Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MorphoSys News Today Immunovant News Today HUTCHMED News Today ImmunityBio News Today Ascentage Pharma Group International News Today Organon & Co. News Today Apellis Pharmaceuticals News Today Xenon Pharmaceuticals News Today Amneal Pharmaceuticals News Today Mirum Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DAWN) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DAWN Stock Free DAWN Stock Alerts